Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Kumashie, Kingsley GideonCebula, Marcin
Hagedorn, Claudia
Kreppel, Florian
Pils, Marina C
Koch-Nolte, Friedrich
Rissiek, Björn
Wirth, Dagmar
Issue Date
2021-02-03
Metadata
Show full item recordAbstract
Chronic hepatotropic viral infections are characterized by exhausted CD8+ T cells in the presence of cognate antigen in the liver. The impairment of T cell response limits the control of chronic hepatotropic viruses. Immune-modulatory strategies are attractive options to re-invigorate exhausted T cells. However, in hepatotropic viral infections, the knowledge about immune-modulatory effects on the in-situ regulation of exhausted intrahepatic CD8+ T cells is limited. In this study, we elucidated the functional heterogeneity in the pool of exhausted CD8+ T cells in the liver of mice expressing the model antigen Ova in a fraction of hepatocytes. We found a subpopulation of intrahepatic CXCR5+ Ova-specific CD8+ T cells, which are profoundly cytotoxic, exhibiting efficient metabolic functions as well as improved memory recall and self-maintenance. The intrahepatic Ova-specific CXCR5+ CD8+ T cells are possibly tissue resident cells, which may rely largely on OXPHOS and glycolysis to fuel their cellular processes. Importantly, host conditioning with CpG oligonucleotide reinvigorates and promotes exhausted T cell expansion, facilitating complete antigen eradication. The CpG oligonucleotide-mediated reinvigoration may support resident memory T cell formation and the maintenance of CXCR5+ Ova-specific CD8+ T cells in the liver. These findings suggest that CpG oligodinucleotide may preferentially target CXCR5+ CD8+ T cells for expansion to facilitate the revival of exhausted T cells. Thus, therapeutic strategies aiming to expand CXCR5+ CD8+ T cells might provide a novel approach against chronic liver infection.Citation
Front Immunol. 2021 Feb 3;11:592328. doi: 10.3389/fimmu.2020.592328.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
FrontiersJournal
Frontiers in immunologyPubMed ID
33613516Type
ArticleLanguage
enEISSN
1664-3224ae974a485f413a2113503eed53cd6c53
10.3389/fimmu.2020.592328
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection.
- Authors: Li Y, Tang L, Guo L, Chen C, Gu S, Zhou Y, Ye G, Li X, Wang W, Liao X, Wang Y, Peng X, Liu G, Zhang X, Sun J, Peng J, Hou J
- Issue date: 2020 Mar
- Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection.
- Authors: He R, Hou S, Liu C, Zhang A, Bai Q, Han M, Yang Y, Wei G, Shen T, Yang X, Xu L, Chen X, Hao Y, Wang P, Zhu C, Ou J, Liang H, Ni T, Zhang X, Zhou X, Deng K, Chen Y, Luo Y, Xu J, Qi H, Wu Y, Ye L
- Issue date: 2016 Aug 2
- CXCR5(+)CD8(+) T Cells Shape Antibody Responses In Vivo Following Protein Immunisation and Peripheral Viral Infection.
- Authors: Tyllis TS, Fenix KA, Norton TS, Kara EE, McKenzie DR, David SC, Alsharifi M, Yu D, McColl SR, Comerford I
- Issue date: 2021
- Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes.
- Authors: Ochel A, Cebula M, Riehn M, Hillebrand U, Lipps C, Schirmbeck R, Hauser H, Wirth D
- Issue date: 2016 Nov
- A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
- Authors: Knuschke T, Kollenda S, Wenzek C, Zelinskyy G, Steinbach P, Dittmer U, Buer J, Epple M, Westendorf AM
- Issue date: 2021 Feb 2